MA55750A - Formulations d'anticorps stables et à faible viscosité et leurs utilisations - Google Patents

Formulations d'anticorps stables et à faible viscosité et leurs utilisations

Info

Publication number
MA55750A
MA55750A MA055750A MA55750A MA55750A MA 55750 A MA55750 A MA 55750A MA 055750 A MA055750 A MA 055750A MA 55750 A MA55750 A MA 55750A MA 55750 A MA55750 A MA 55750A
Authority
MA
Morocco
Prior art keywords
stable
low
antibody formulations
viscosity antibody
viscosity
Prior art date
Application number
MA055750A
Other languages
English (en)
Inventor
Manjori Ganguly
Yatin Gokarn
Kelvin Rembert
Atul Saluja
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA55750A publication Critical patent/MA55750A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055750A 2019-04-23 2020-04-23 Formulations d'anticorps stables et à faible viscosité et leurs utilisations MA55750A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
EP20305145 2020-02-17

Publications (1)

Publication Number Publication Date
MA55750A true MA55750A (fr) 2022-03-02

Family

ID=70295163

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055750A MA55750A (fr) 2019-04-23 2020-04-23 Formulations d'anticorps stables et à faible viscosité et leurs utilisations

Country Status (15)

Country Link
US (1) US20220218607A1 (fr)
EP (1) EP3958896A1 (fr)
JP (1) JP2022530050A (fr)
KR (1) KR20220004104A (fr)
CN (1) CN114286690A (fr)
AU (1) AU2020262231A1 (fr)
BR (1) BR112021021099A2 (fr)
CA (1) CA3137464A1 (fr)
CO (1) CO2021015561A2 (fr)
IL (1) IL287435A (fr)
MA (1) MA55750A (fr)
MX (1) MX2021012968A (fr)
SG (1) SG11202111740PA (fr)
TW (1) TW202108171A (fr)
WO (1) WO2020216847A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
EP4069743A1 (fr) * 2019-12-05 2022-10-12 Sanofi-Aventis U.S. LLC Formulations d'anticorps anti-cd38 pour administration sous-cutanée
WO2024023843A1 (fr) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited Formulation pharmaceutique d'un anticorps thérapeutique et ses préparations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
PE20121530A1 (es) 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
JP2013507928A (ja) 2009-10-15 2013-03-07 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI505838B (zh) * 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
WO2012018790A2 (fr) 2010-08-03 2012-02-09 Abbott Laboratories Immunoglobulines à double domaine variable et utilisations associées
AR093557A1 (es) * 2012-11-20 2015-06-10 Sanofi Sa Anticuerpos anti-ceacam5 y usos de estos
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
US20200087390A1 (en) * 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
EP3559033A1 (fr) * 2016-12-22 2019-10-30 Sanofi Anticorps cxcr3 humanisés ayant une activité de déplétion et leurs procédés d'utilisation

Also Published As

Publication number Publication date
AU2020262231A1 (en) 2021-12-16
JP2022530050A (ja) 2022-06-27
BR112021021099A2 (pt) 2021-12-14
SG11202111740PA (en) 2021-11-29
MX2021012968A (es) 2022-01-18
CA3137464A1 (fr) 2020-10-29
KR20220004104A (ko) 2022-01-11
CN114286690A (zh) 2022-04-05
WO2020216847A1 (fr) 2020-10-29
EP3958896A1 (fr) 2022-03-02
IL287435A (en) 2021-12-01
TW202108171A (zh) 2021-03-01
CO2021015561A2 (es) 2021-12-10
US20220218607A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
MA55750A (fr) Formulations d'anticorps stables et à faible viscosité et leurs utilisations
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
MA52970A (fr) Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
MA49565A (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA52414A (fr) Anticorps agonistes de pd-1 et leurs utilisations
MA54947A (fr) Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
MA56517A (fr) Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations
MA53122A (fr) Variants d'anticorps cd38 et leurs utilisations
MA54195A (fr) Conjugués d'interleukine 10 et leurs utilisations
MA51903A (fr) Formulations d'anticorps b7-h4
FR2912310B1 (fr) Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications.
MA52174A (fr) Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques
MA56205A (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA51634A (fr) Oligonucléotides antisens d'alpha-synucléine et leurs utilisations
MA52411A (fr) Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
MA52094A (fr) Anticorps anti-il-27 et leurs utilisations
MA55491A (fr) Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
MA54148A (fr) Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation
MA54051A (fr) Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations